Metastatic breast cancer patients who have stable disease following treatment of anthracycline plus Taxol (paclitaxel) might not be receiving any benefit if they are receiving maintenance Taxol after first-line treatment.
It seems that it might not do any good. A study was done that showed the two groups, one with the maintenance Taxol and the one without, having outcomes that had no differences. Neither group showed any difference in progression free survival.
The study was based on 255 women that had stable disease. It could be a good idea to mention this article that was in the Journal of Clinical Oncology to your oncologist if you are receiving maintenance Taxol for metastatic breast cancer.











1. Touche on your information Kristina. And when you consider the toxic profiles of Taxol, it makes even more sense.
http://www.oncolink.com/resources/article.cfm?c=3&s=8&ss=23&Year=2006&Month=08&id=13457
Posted at 1:55AM on Sep 2nd 2006 by Gregory D. Pawelski